Agilent Awards Influential Clinical Genomics Researcher
News Nov 29, 2016
Agilent Technologies Inc. announced that Peter Robinson, M.D., MSC, has received an Agilent Thought Leader Award in recognition of his contributions to clinical genomics and computational biology.
The award includes funding that will enable Dr. Robinson to extend his research efforts to identify non-coding regions of the genome involved in gene regulation and disease. Of particular interest are those regions located far away from the genes they regulate or ‘enhancer’ regions that typically escape exome sequencing analysis.
“Dr. Robinson focuses on the identification of enhancer mutations involved in various human diseases and conditions. His research will increase our understanding of the disease relevance of regulatory regions in the genome, as well as demonstrate the utility of targeted sequence capture for such studies," said Herman Verrelst, Agilent vice president and general manager, Genomics and Clinical Applications Division, and the executive sponsor of this award. "We are pleased to support Dr. Robinson’s work in this important area,” added Verrelst.
“I’m very grateful for this award as it will allow us to examine the influence of DNA variation and dysregulation of gene regulation in immune cells, as well as cohorts of patients with diseases of the immune system, in order to address the hypothesis that alterations of enhancer-promoter looping interactions may underlie some forms of immunological disease,” said Dr. Robinson. “The work will involve genomics investigations in which relevant regulatory regions of the genome are enriched and subjected to next-generation sequencing. We will also develop bioinformatics pipelines and algorithms in order to process and analyse the resulting data, as well as software methods for biological and medical interpretation, with the goal of establishing robust methods for the use of this kind of genomics to investigate the disease relevance of non-coding regions of our genome,” he added.
Story from Agilent Technologies. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE